Vasgen Limited (“Vasgen” or “the Company”), a new speciality biotech company, reports that it will be attending the 2013 Genesis Conference in London UK.
Organised by One Nucleus, the 2013 conference is focused on the theme of “innovative strategies to bridge the R & D gap.” Dr Salman Rahman, CEO and co-founder of Vasgen said: “We look forward to this year’s conference which comes at a time of increased optimism for the economy as a whole and for the sector in particular. We hope this translates into increased investment for early-stage biotech companies in 2014.”
-Ends-
Notes to Editors
Vasgen Limited is a new London-based biotech company developing innovative ocular and cancer therapeutics to meet unmet clinical needs. The Company’s technologies include AbIMP®, a novel antibody-based approach allowing development of highly selective inhibitors of metalloproteinase catalytic activity with a particular focus on the ADAMs gene family of sheddases. The Company’s lead product under development is a pre-clinical stage therapeutic AbIMP targeting ADAM15 for anti-angiogenesis therapy. More information is available at www.vasgen.co.uk
For further information please contact:
Tel : +44 (0)207 691 2149